We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.40 | -1.12% | 35.40 | 35.45 | 36.10 | 36.20 | 35.00 | 35.80 | 241,540 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.66 | 108.86M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/4/2024 19:45 | A good read...... | broomrigg | |
19/4/2024 18:52 | APH? That's a brave recommendation! | petroc | |
19/4/2024 17:08 | Best value healthcare company is APH (alliancepharma )-record revenues up 6% to £182.7m-FY24 profit guideline £50m-strong consumer demand -Free cash flow up 34% to £21.1m | blackhorse23 | |
19/4/2024 17:05 | No revenue with 102m mcap ??? | blackhorse23 | |
17/4/2024 08:41 | all of those website are working apart from Italy, well wasn't yesterday | keifer derrin | |
16/4/2024 14:20 | Posted on LSE, Portugal website up and running..... | broomrigg | |
16/4/2024 14:19 | More like Futura does not make progress. Except on removing the reminders of all the other products that produced nothing like was claimed to be expected back when they launched. ‘PET500 is expected to produce royalties of between £8m and £10m a year’ | mdi | |
16/4/2024 11:10 | All references to PET500/Epic spray have now vanished from the Futura website? January 2014 Futura Medical Epic launch by Ansell in US market ˜The financial terms of the Ansell worldwide licensing agreement are not disclosed but Futura Medical estimates that a 5% share of the global OTC performance-enhancem | mdi | |
16/4/2024 10:34 | More information has been again taken down from the Futura website. As happened before and was previously written about ‘The vanishing FAQ’ The Erection of a Placebo When yesterday's placebo is tomorrow's treatment | mdi | |
16/4/2024 09:56 | I think he finishes his security shift at 8 in the morning, so he probably has. He must have forgotten to take his crayons last night because he didn't share his 'special' knowledge about Erexon/Eroxon, for a change! | petroc | |
16/4/2024 07:16 | When do you reckon Glavey? | broomrigg | |
16/4/2024 04:35 | Notable spend on plant & equipment last financial year - wonder what they bought. Anyone have any ideas as to the timing of the next cash raise? | glavey | |
15/4/2024 23:37 | Also according to Ceuta if ‘Online provided the majority of sales’ for Eroxon. Is that how Futura were able come up with the market share they touted in the RNS that Eroxon supposedly captured in the early days of launching in UK and Belgium of ‘c. 20% market share of approved ED treatments’. So Eroxon actually just captured 20% of a smalll online market of approved ED treatments ie mainly online sales of other medical devices which are also all ‘approved ED treatments. But which mostly excludes the online sale of drugs like Viagra, Cialis etc. As online sales are mostly an ’option not open to “pharmacy&rdqu | mdi | |
15/4/2024 21:38 | And yet another contradiction to what Futura told shareholders. The UK distributor Ceuta Healthcare, marketing director Jon Connolly said ‘Online provided the majority of sales’ ‘While physical sales were “kind of slow”. So again they could track the majority of online sales and give a repurchase rate.But maybe they didn’t want more detailed figures. As it already appears to be obvious from the declining revenues what is happening. Eroxon revenue was £1.7m in April/May and only £1.4m in the following 6 months | mdi | |
15/4/2024 20:32 | MDI, it's impossible to underestimate you. There was a little too much chlorine in your gene pool. You don’t need to fear success, you have nothing to worry about. | petroc | |
15/4/2024 19:48 | Here is another contradiction to what was claimed in the Futura presentation. About them not being unable to provide any details to shareholders on repeat purchasers? ‘If a someone wants to buy Eroxon on Amazon, their credit card details and delivery addresses are already there’ | mdi |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions